NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading DCTH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on revenue growth and margin maintenance. The current thesis state is intact, but it faces medium confidence due to recent financial performance being neutral.
The market currently prices DCTH at a premium compared to its peers, reflecting a justified valuation. There is no expectations gap, indicating that the market has already factored in the company's current performance and outlook.
Management is on track to achieve its revenue target of at least $100 million for 2026 and maintain gross margins between 84% and 87%. However, the goal of positive adjusted EBITDA in 2026 is mixed, suggesting some uncertainty in that area.
The long-term thesis hinges on sector performance, particularly the results and guidance from major players like ABT, SYK, and MDT. If these companies continue to perform well, it could support DCTH's growth; conversely, any negative shifts could impact DCTH's trajectory.
Overall, DCTH's fundamentals appear stable, but the elevated risk and sector dependence warrant close monitoring. Not investment advice.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. There are no new strengths or weaknesses identified that would alter the current assessment. The overall fundamentals remain intact, with recent financial performance holding steady in the top half of its industry.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting this target would support the goal of at least $100M in revenue for 2026. It shows strong demand for HEPZATO KIT.
Confirms:Q2 revenue growth of at least 20% year over year compared to Q2 2025.
Disproves:Q2 revenue growth falls below 15% year over year.
Why it matters: Keeping margins high is important for making money. It matches what management wants.
Confirms:Gross margins above 84% would show good cost management.
Disproves:Gross margins below 80% suggest possible cost problems.
Why it matters: If health care revenue growth picks up, it could boost Delcath's outlook.
Confirms:Health care revenue growth shows a return to above 10% year-over-year.
Disproves:Revenue growth is still below 10% compared to last year.
Why it matters: Keeping this range is important for making money. It matches management's goals for 2026.
Confirms:Gross margins reported in Q2 remain within the 84% to 87% range.
Disproves:Gross margins reported in Q2 drop below 84%.
Why it matters: Good news could increase HEPZATO KIT sales. It would also confirm its clinical benefits.
Confirms:Reports show a big rise in prescriptions for HEPZATO KIT after the CHOPIN trial.
Disproves:No change in prescribing patterns after the CHOPIN trial results are published.
